SCHEMBL3522740

SCHEMBL3522740

COC(=O)c1c(OC)ccc2nc(-c3ccccc3)c(Cl)nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.46
PLA2G2A P14555 1/20 0.45
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 3/20 0.43
PKM P14618 1/20 0.43
PTGS1 P23219 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 5/20 0.43
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 2/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
KEAP1 Q14145 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519204 0.95 PLA2G2A (0.45) DHODHPLA2G2AMEN1KMT2AKDM4E
SCHEMBL3518290 0.90 NPSR1 (0.49) DHODHMEN1KMT2AKDM4EPTGS1
SCHEMBL3524998 0.78 ECE1 (0.52) DHODHMEN1KMT2AKDM4EPTGS1
SCHEMBL3528832 0.78 ECE1 (0.52) DHODHMEN1KMT2AKDM4EPTGS1
SCHEMBL3522479 0.78 PGK1 (0.44) DHODHPLA2G2AMEN1KMT2AKDM4E
SCHEMBL3517477 0.78 ALDH1A1 (0.42) DHODHPLA2G2AMEN1KMT2AKDM4E
SCHEMBL3521893 0.77 SMN1; SMN2 (0.52) DHODHPLA2G2AMEN1KMT2AKDM4E
SCHEMBL3753086 0.77 SMN1; SMN2 (0.52) DHODHPLA2G2AALDH1A1GABRA1GABRG2
SCHEMBL3517826 0.75 DHODH (0.45) DHODHKMT2AKDM4EPTGS1NPSR1
SCHEMBL3520256 0.74 ALDH1A1 (0.49) PLA2G2AMEN1KMT2AKDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101983384-A Prolyl hydroxylase inhibitors SMITHKLINE BEECHAM CORP 2011-03-02 CN disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 DHODH 20/4885PLA2G2A 4495/4885MEN1 2552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.